Danaher Corporation (DHR) 株式分析

企業概要

Danaher Corporation is a leading global enterprise that designs, manufactures, and markets professional, medical, research, and industrial products and services across the United States, China, and international markets. The corporation operates primarily within the Healthcare sector, specifically focusing on the Diagnostics & Research industry, which positions it at the intersection of advanced biotechnology and life sciences innovation. This massive scale is reflected in a market capitalization of $136.58B and an annual revenue of $24.57B, supported by a workforce of 58000 employees. These valuation metrics and revenue figures indicate that the company commands a substantial position within the healthcare ecosystem, serving diverse segments including Biotechnology, Life Sciences, and Diagnostics.

財務健全性

The company reported a revenue of $24.57B and a net income of $3.60B for the trailing twelve months, while generating an EBITDA of $7.83B. The significant gap between the $24.57B revenue and the $3.60B net income reveals a substantial cost structure comprising cost of goods sold, operating expenses, and taxes that consumes approximately 85.3% of gross revenue before reaching the bottom line. The company maintains robust free cash flow of $4.55B, which provides significant financial flexibility for capital allocation, debt repayment, or potential acquisitions without relying on external financing. Profitability analysis shows a gross margin of 59.2%, an operating margin of 22.2%, and a profit margin of 14.7%, indicating strong pricing power and efficient operational control at the gross level before non-operating costs impact the final profit. On the balance sheet, the company holds $4.62B in cash against $19.70B in debt, resulting in a debt-to-equity ratio of 37.49, which suggests a leveraged balance sheet where equity capital is significantly lower than total debt obligations. Despite the leverage, the current ratio stands at 1.87, indicating that current assets are nearly double current liabilities and reflecting a healthy position for meeting short-term liquidity obligations. Return on Equity is 7.1% and Return on Assets is 4.2%, metrics that provide insight into how effectively management utilizes shareholder capital and total assets to generate profits, though the ROA is modest relative to the leverage present.

バリュエーション評価

Valuation metrics show a P/E Ratio (TTM) of 38.29 compared to a Forward P/E of 21.19, implying that the market expects earnings to grow significantly in the future to justify the high trailing multiple. The price-to-book ratio is 2.60, indicating that the stock trades at a premium of 2.6 times its book value, which reflects investor confidence in the company's intangible assets and future earning potential beyond its tangible net worth. Alternative valuation measures include a price-to-sales ratio of 5.56 and an EV/EBITDA of 19.34, suggesting the market values the company's cash flow generation and sales volume at a rate that is sensitive to interest rate environments and growth expectations. The stock's trading range over the past year spans from a low of $171.00 to a high of $242.80, providing a clear historical context for assessing current valuation levels relative to recent volatility. The beta of 0.99 indicates that the stock's price volatility moves in lockstep with the broader market, meaning it does not exhibit significantly higher or lower systematic risk compared to the overall index.

Growth & Income

Revenue growth stands at 4.6% year-over-year while earnings growth reaches 12.5% year-over-year, demonstrating that earnings are expanding at a rate more than double that of revenue. This divergence implies that the company is improving its profitability per unit sold through margin expansion or cost efficiencies rather than solely relying on top-line volume increases. As a dividend payer, the company offers a dividend yield of 0.8% with a payout ratio of 25.4%, indicating that the dividend payments are highly sustainable given that only a quarter of net income is distributed to shareholders. The low payout ratio leaves ample room for reinvestment into research, development, and operational capabilities to fund organic growth and strategic inorganic opportunities. The overall profile combines steady revenue expansion with accelerating earnings growth and a conservative yet sustainable dividend policy, creating a balanced income and capital appreciation opportunity within the healthcare sector.